Drug Trial Radar · NCT07897448
A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
105
Planned (sponsor's estimate)
Start
Oct 31, 2026
Primary completion
Sep 22, 2028
Study completion Jun 20, 2029
Sponsor
- Lead sponsor
- Grand Theravac Life Sciences (Hangzhou) Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Ausper Biopharma Co., Ltd.
- First posted
- Oct 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study of sequential therapy with AHB-137 injection followed by TVAX-008 injection in participants living with Chronic Hepatitis B (CHB).
Conditions
- Chronic Hepatitis B
Interventions
AHB-137Drug
AHB-137 will be administered per 1 week
TVAX-008Drug
TVAV-008 will be administered per 4 weeks
AHB-137Drug
AHB-137 will be administered per 1 week
PlaceboDrug
Placebo will be used per 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) in Phase ITime frame: From the first dose of study treatment through the last study visit (up to Week 72)
- Percentage of Participants Achieving Clinical Cure (Functional Cure) at 24 Weeks After Discontinuation of All Chronic Hepatitis B Treatments in Phase IITime frame: 24 weeks after discontinuation of all chronic hepatitis B treatments (up to Week 72)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.